English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/230881
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort

AuthorsLópez-Medrano, Francisco; Silva, José Tiago; Fernández-Ruiz, Mario; Vidal, Elisa; Origüen, Julia; Calvo-Cano, Antonia; Luna-Huerta, Enrique; Merino, Esperanza; Hernández, Domingo; Jironda‐Gallegos, Cristina; Escudero Sánchez, Rosa; Gioia, Francesca; Moreno, Antonio; Roca-Oporto, Cristina; Cordero, Elisa; Janeiro, Darío; Sánchez-Sobrino, Beatriz; Montero, Milagros; Redondo, Dolores; Candel, Francisco Javier; Pérez-Flores, Isabel; Armiñanzas Castillo, Carlos; González-Rico, Claudia; Fariñas, María del Carmen; Rodrigo, Emilio; Loeches, Belén; López‐Oliva, María O.; Montejo, Miguel; Lauzurica, Ricardo; Horcajada, Juan Pablo; Pascual, Julio; Andrés, Amado; Aguado, José María
KeywordsAntibiotics
Clinical research/practice
Infection and infectious agents ‐ bacterial
Infectious disease
Kidney transplantation/nephrology
Issue DateFeb-2020
PublisherJohn Wiley & Sons
CitationAmerican Journal of Transplantation 20(2): 451-462 (2020)
AbstractOral fosfomycin may constitute an alternative for the treatment of lower urinary tract infections (UTIs) in kidney transplant recipients (KTRs), particularly in view of recent safety concerns with fluroquinolones. Specific data on the efficacy and safety of fosfomycin in KTR are scarce. We performed a retrospective study in 14 Spanish hospitals including KTRs treated with oral fosfomycin (calcium and trometamol salts) for posttransplant cystitis between January 2005 and December 2017. A total of 133 KTRs developed 143 episodes of cystitis. Most episodes (131 [91.6%]) were produced by gram‐negative bacilli (GNB), and 78 (54.5%) were categorized as multidrug resistant (including extended‐spectrum β‐lactamase‐producing Enterobacteriaceae [14%] or carbapenem‐resistant GNB [3.5%]). A median daily dose of 1.5 g of fosfomycin (interquartile range [IQR]: 1.5‐2) was administered for a median of 7 days (IQR: 3‐10). Clinical cure (remission of UTI‐attributable symptoms at the end of therapy) was achieved in 83.9% (120/143) episodes. Among those episodes with follow‐up urine culture, microbiological cure at month 1 was achieved in 70.2% (59/84) episodes. Percutaneous nephrostomy was associated with a lower probability of clinical cure (adjusted odds ratio: 10.50; 95% confidence interval: 0.98‐112.29; P = 0.052). In conclusion, fosfomycin is an effective orally available alternative for treating cystitis among KTRs.
DescriptionPreliminary results of this study were presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), held in Amsterdam, The Netherlands, from 13 to 16 April, 2019 (oral communication O‐0699).
Publisher version (URL)http:/.doi.org/10.1111/ajt.15614
URIhttp://hdl.handle.net/10261/230881
Identifiersdoi: 10.1111/ajt.15614
issn: 1600-6135
e-issn: 1600-6143
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.